IRIS
MENNA, PIERANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.988
NA - Nord America 2.520
EU - Europa 937
SA - Sud America 222
Continente sconosciuto - Info sul continente non disponibili 113
AF - Africa 45
OC - Oceania 13
Totale 8.838
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.606
US - Stati Uniti d'America 2.337
CN - Cina 684
IT - Italia 395
HK - Hong Kong 373
BR - Brasile 135
GB - Regno Unito 135
FR - Francia 96
DE - Germania 92
CA - Canada 66
VN - Vietnam 66
BD - Bangladesh 59
CZ - Repubblica Ceca 54
IN - India 45
MX - Messico 44
RU - Federazione Russa 28
FI - Finlandia 26
NL - Olanda 26
AR - Argentina 22
CO - Colombia 21
ID - Indonesia 18
PH - Filippine 18
CR - Costa Rica 15
EC - Ecuador 13
ES - Italia 13
IL - Israele 13
ZA - Sudafrica 13
AU - Australia 12
MY - Malesia 12
SC - Seychelles 12
UA - Ucraina 12
VE - Venezuela 12
PL - Polonia 11
TR - Turchia 11
NI - Nicaragua 10
SA - Arabia Saudita 10
JP - Giappone 9
PK - Pakistan 9
GP - Guadalupe 8
JM - Giamaica 8
PY - Paraguay 8
SV - El Salvador 8
CL - Cile 7
EE - Estonia 7
TT - Trinidad e Tobago 7
TW - Taiwan 7
BE - Belgio 6
GT - Guatemala 6
IQ - Iraq 6
JO - Giordania 6
MD - Moldavia 6
AE - Emirati Arabi Uniti 5
HN - Honduras 5
NP - Nepal 5
PT - Portogallo 5
AL - Albania 4
IE - Irlanda 4
TH - Thailandia 4
UZ - Uzbekistan 4
AT - Austria 3
GE - Georgia 3
KR - Corea 3
LT - Lituania 3
SE - Svezia 3
TN - Tunisia 3
AO - Angola 2
BO - Bolivia 2
CI - Costa d'Avorio 2
CW - ???statistics.table.value.countryCode.CW??? 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EG - Egitto 2
MA - Marocco 2
MM - Myanmar 2
PE - Perù 2
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CV - Capo Verde 1
DM - Dominica 1
ET - Etiopia 1
GA - Gabon 1
KG - Kirghizistan 1
KH - Cambogia 1
KN - Saint Kitts e Nevis 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
ME - Montenegro 1
MR - Mauritania 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
Totale 8.722
Salva come PNG Salva come JPEG
Città #
San Jose 563
Ashburn 471
Singapore 409
Hong Kong 370
Rome 247
Beijing 210
Hefei 184
Council Bluffs 131
Boardman 107
Columbus 100
London 83
Lauterbourg 79
Dallas 68
Santa Clara 68
Shanghai 61
Munich 48
Los Angeles 46
Brno 35
Phoenix 31
New York 28
Mexico City 26
San Francisco 26
Ho Chi Minh City 22
Pune 20
Redmond 20
Amsterdam 19
São Paulo 18
Olomouc 17
Hanoi 15
Turku 14
Seattle 13
Washington 13
Guangzhou 12
San José 12
Toronto 12
Brooklyn 11
Chicago 11
Helsinki 11
Manchester 11
Montreal 11
Milan 10
Naples 10
Boston 9
Brasília 9
Managua 9
Warsaw 9
Bogotá 8
Nuremberg 8
Orem 8
Tokyo 8
Las Vegas 7
North Bergen 7
Rio de Janeiro 7
San Salvador 7
Buffalo 6
Caracas 6
Kuala Lumpur 6
Melbourne 6
Palermo 6
Philadelphia 6
Amman 5
Atlanta 5
Campinas 5
Chennai 5
Frankfurt am Main 5
Guatemala City 5
Guayaquil 5
Haiphong 5
Hangzhou 5
Johannesburg 5
Riyadh 5
The Dalles 5
Ankara 4
Biên Hòa 4
Chaguanas 4
Charlotte 4
Dhaka 4
Haikou 4
Manila 4
New Delhi 4
Paris 4
Piscataway 4
Québec 4
Taipei 4
Tashkent 4
Tirana 4
Wuhan 4
Alessandria 3
Buenos Aires 3
Burlington 3
Canberra 3
Colombo 3
Columbia 3
Curitiba 3
Dublin 3
Florence 3
Genoa 3
Hanover 3
Hyderabad 3
Istanbul 3
Totale 3.964
Salva come PNG Salva come JPEG
Nome #
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 244
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 242
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 225
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 222
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 214
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 212
Cancer drugs and QT prolongation: weighing risk against benefit 212
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 209
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 208
Minimal sampling colistin pharmacokinetics in critically ill patients 208
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 207
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 202
Cardio-oncology in clinical studies and real life 193
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 185
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 170
Anthracycline Cardiotoxicity 158
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 149
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 142
Anthracyclines 138
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 137
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 129
Anthracycline Cardiotoxicity 120
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 117
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 116
Cardiotoxicity of antitumor drugs 111
An introduction to the metabolic determinants of anthracycline cardiotoxicity 110
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 109
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 109
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 108
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 105
Isavuconazole: case report and pharmacokinetic considerations 93
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 86
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 84
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 82
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 79
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 79
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 78
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 75
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 75
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 72
Pharmacology of Cardio-Oncology 72
The concomitant management of cancer therapy and cardiac therapy 71
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples 70
What is cardiotoxicity? 70
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 69
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 69
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 69
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 68
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 67
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 67
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 67
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 66
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 66
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 64
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 64
Pharmacological Foundation of Cardio-Oncology 62
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 60
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 59
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 58
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 56
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 55
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 54
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 52
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 52
Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry 52
Doxorubicin degradation in cardiomyocytes 51
The reality of pixantrone in real life 51
Matters of the heart: The case of TNF-alpha targeting drugs 51
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 51
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 51
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 50
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 50
Molecular determinants of the reduced cardiotoxicity of epirubicin 50
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 50
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 48
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 48
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 48
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 46
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 46
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 46
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 46
Translating molecular mechanisms into clinical facts 45
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 45
Recommendations for the harmonization of reference intervals in the therapeutic monitoring of antiepileptic drugs/Indicazioni per l’armonizzazione degli intervalli di riferimento nel monitoraggio terapeutico di farmaci antiepilettici 44
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition J. Biol. Chem 44
Do you know pixantrone? 43
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 42
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 42
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 42
Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study 41
In ®Entresto we trust 41
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 41
Humans and Rodents: The Case of hOAT4 and mOat5 40
Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 39
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib 27
Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind? 26
Indications for the harmonization of the therapeutic ranges for antifungal agents 16
Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in Italy 16
Bruton tyrosine kinase inhibitors and cardiovascular adverse events 14
Optimizing Treatment, Minimizing Risk: Therapeutic Drug Monitoring in Hematological Malignancies 11
Totale 8.835
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.411
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.411
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022214 0 0 0 0 0 0 1 92 4 0 5 112
2022/202356 2 1 1 4 2 2 15 0 3 3 22 1
2023/2024333 6 35 11 15 37 146 1 16 2 8 4 52
2024/20254.043 102 36 123 15 45 77 40 21 250 263 1.446 1.625
2025/20262.976 336 204 131 250 139 94 923 205 219 257 106 112
2026/20271.212 74 334 370 434 0 0 0 0 0 0 0 0
Totale 8.838